Shah DK - Search Results

1

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.

Shah DK, Haddish-Berhane N, Betts A. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):643-59. doi: 10.1007/s10928-012-9276-y. Epub 2012 Nov 15. J Pharmacokinet Pharmacodyn. 2012. PMID: 23151991

2

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Shah DK, Betts AM. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):67-86. doi: 10.1007/s10928-011-9232-2. Epub 2011 Dec 6. J Pharmacokinet Pharmacodyn. 2012. PMID: 22143261

3

Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.

Shah DK, Betts AM. Shah DK, et al. MAbs. 2013 Mar-Apr;5(2):297-305. doi: 10.4161/mabs.23684. Epub 2013 Feb 13. MAbs. 2013. PMID: 23406896 Free PMC article.

4

Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.

Shah DK, Barletta F, Betts A, Hansel S. Shah DK, et al. Bioanalysis. 2013 May;5(9):989-92. doi: 10.4155/bio.13.78. Bioanalysis. 2013. PMID: 23641690 No abstract available.

5

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. Haddish-Berhane N, et al. Among authors: shah dk. J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10. J Pharmacokinet Pharmacodyn. 2013. PMID: 23933716

6

A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.

Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, Haddish-Berhane N, Betts A, Leal M. Shah DK, et al. AAPS J. 2014 May;16(3):452-63. doi: 10.1208/s12248-014-9576-9. Epub 2014 Mar 1. AAPS J. 2014. PMID: 24578215 Free PMC article.

7

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. Leal M, et al. Among authors: shah dk. Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499. Ann N Y Acad Sci. 2014. PMID: 25123209 Review.

8

Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).

Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. Singh AP, et al. Among authors: shah dk. AAPS J. 2016 Jul;18(4):861-75. doi: 10.1208/s12248-016-9904-3. Epub 2016 Mar 30. AAPS J. 2016. PMID: 27029797 Free PMC article.

9

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.

Singh AP, Sharma S, Shah DK. Singh AP, et al. Among authors: shah dk. J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):567-582. doi: 10.1007/s10928-016-9495-8. Epub 2016 Sep 26. J Pharmacokinet Pharmacodyn. 2016. PMID: 27670282 Free PMC article.

10

Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.

Shah DK, Loganzo F, Haddish-Berhane N, Musto S, Wald HS, Barletta F, Lucas J, Clark T, Hansel S, Betts A. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):339-349. doi: 10.1007/s10928-018-9577-x. Epub 2018 Feb 8. J Pharmacokinet Pharmacodyn. 2018. PMID: 29423862

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

279 results

Search Page

Filters